Wall $t Banker$$

[micasey123]

DJ Hollis-Eden Pharmaceuticals Responds To Sources Sought Notice From Department Of Defense For Acute Radiation Syndrome Therapy For U.S. Forces>HEPH

01/31/2006
Dow Jones News Services
(Copyright © 2006 Dow Jones & Company, Inc.)



(MORE TO FOLLOW) Dow Jones Newswires

01-31-06 0700ET

Copyright (c) 2006 Dow Jones & Company, Inc.

*DJ Hollis-Eden Received Sources Sought Notice From Defense Dept



(MORE TO FOLLOW) Dow Jones Newswires

01-31-06 0714ET

Copyright (c) 2006 Dow Jones & Company, Inc.

*DJ Hollis-Eden Received Letter From Defense Dept It Plans To Issue RFP



(MORE TO FOLLOW) Dow Jones Newswires

01-31-06 0714ET

Copyright (c) 2006 Dow Jones & Company, Inc.

DJ Hollis-Eden Responds To DOD Inquiry For Radiation Drug


SAN DIEGO (Dow Jones)--Hollis-Eden Pharmaceuticals Inc. (HEPH) has responded to a Sources Sought Notice, or SSN, from the Department of Defense concerning the development of medical radiation countermeasures.

In a press release Tuesday, the pharmaceutical company said it also received a letter from the Defense Department indicating that it intends to issue a Request for Proposal, or RFP, for medical radiation countermeasures in the first half of 2006 and that it encourages Hollis-Eden to respond to the RFP once issued. The SSN is the first step in this procurement process, the company noted.

The company said the purpose of the SSN is to identify companies that believe they have viable candidate drugs that can be expeditiously developed and will provide a safe and effective countermeasure against radiation injury. Hollis-Eden believes its drug candidate, Neumune, might offer a practical medical countermeasure that can be deployed with U.S. military personnel to provide protection from acute radiation injury.

Neumune is being developed under the Food and Drug Administration's "Animal Rule" for medical countermeasures to weapons of mass destruction. Under this rule, regulatory approval is based on efficacy demonstrated in relevant animal models and safety data in humans.

-Thomas Gryta; Dow Jones Newswires; 201-938-5400; [e-mail]


Order free Annual Report for Hollis-Eden Pharmaceuticals Inc.

Visit http://djnewswires.ar.wilink.com/?link=HEPH or call 1-888-301-0513

(END) Dow Jones Newswires

01-31-06 0748ET

Copyright (c) 2006 Dow Jones & Company, Inc.